Molecular Templates, Inc., a biopharmaceutical company focused on novel cancer therapies, was notified on December 16, 2024, by Nasdaq that the company is considered a "public shell" and its securities would be delisted due to non-compliance with rules regarding timely financial filings and bid price maintenance. The stock will be suspended on December 26, 2024, unless the company requests a hearing to appeal Nasdaq's decision. Molecular Templates does not plan to request a hearing, so the trading of its common stock is expected to be suspended on the given date. This news comes after the company failed to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024.